Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer
Authors:
- Gee Young LeeGLGee Young Lee
- Mohamed MubasherMMMohamed Mubasher
- Tamra S. McKenzieTMTamra S. McKenzie
- Nicole C. SchmittNSNicole C. Schmitt
- Merry E. SebelikMerry E. Sebelik
- Carrie E. FlanaganCFCarrie E. Flanagan
- Badi El OstaBOBadi El Osta
- Maya B. CothranMCMaya B. Cothran
- Hadiyah-Nicole GreenHGHadiyah-Nicole Green
Open Access
Abstract
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.Keywords
All Related Versions
Funding Information
- Biomedical Laboratory Research and Development, VA Office of Research and Development (I01BX007080)
- National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR000454)
- National Cancer Institute (P30CA013148, P50CA098252, U54CA118938, U54CA118623, U54CA118948)
This publication has 44 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour siteRadiotherapy and Oncology, 2011
- Guidelines for accurate EC50/IC50 estimationPharmaceutical Statistics, 2011
- Trastuzumab-Functionalized Nanoparticles of Biodegradable Copolymers for Targeted Delivery of DocetaxelNanomedicine, 2009
- Docetaxel in the management of patients with head and neck squamous cell carcinomaExpert Review of Anticancer Therapy, 2008
- Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation TaxanesChemMedChem, 2007
- Simulation of the Optical Absorption Spectra of Gold Nanorods as a Function of Their Aspect Ratio and the Effect of the Medium Dielectric ConstantThe Journal of Physical Chemistry B, 2005
- DocetaxelDrugs, 2005
- DocetaxelDrugs, 2000
- Docetaxel in Head and Neck CancerAmerican Journal of Clinical Oncology, 1998